Yuxian Du, PhD

Associate Director
Johnson & Johnson

Poster(s):

• (280) An economic model assessing costs, relapses, and antipsychotic adherence of switching Medicaid beneficiaries with schizophrenia from oral antipsychotics to once-monthly, once-every-three-months, and once-every-six-months paliperidone palmitate
  Wednesday, October 29, 2025